Loading stock data…
Celcuity Inc (CELC)
$102.52+2.57 (+2.57%)
After Hours$103.00+0.48 (+0.47%)· Last close Jun 29
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Celcuity Inc. in the Healthcare sector is trading at $102.52 with a market capitalization of $4.3B. Wall Street consensus targets $160.64 (11 analysts), implying a +56.7% move over the next 12 months. The stock is currently 32% below its 52-week high of $151.02, remaining 4.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +56.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.51M↓ | -$49.20M↓ | -$42.85M↑ | -$44.01M↓ | -$36.13M |
| Net Income | -$52.84M↓ | -$50.97M↓ | -$43.80M↑ | -$45.27M↓ | -$37.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.25B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-360.37%
Volume
Today's trading volume
965,680
Recent News
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, overnight. Read that last number again. This stock nearly doubled in a single session. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, I could just tell you “wow, what a move” and carry on with my day. But that’s not what I do, and it’s not wh
Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering
In recent days, Celcuity Inc. completed a US$500 million offering of 0.250% convertible senior notes due August 1, 2032, shortly after releasing detailed Phase 3 VIKTORIA-1 data for its investigational breast cancer drug gedatolisib in PIK3CA-mutant patients. The trial results showed gedatolisib-based regimens cutting the risk of disease progression or death by about half versus alpelisib plus fulvestrant, while the company moves toward supplemental FDA filings on top of an ongoing Priority...
Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients
Celcuity Inc. (NASDAQ:CELC) is one of the best high short interest stocks with highest upside potential. On May 14, Celcuity announced amendments to its Phase 3 VIKTORIA-2 clinical trial, which evaluates gedatolisib as a first-line treatment for hormone receptor-positive, HER2-negative advanced breast cancer. The study will now expand to include a separate cohort for endocrine-sensitive […]
US Equity Futures Mixed Pre-Bell as US, Iran Continue Military Strikes in Middle East
US equity futures were mixed pre-bell Wednesday as the US and Iran exchanged military strikes in the
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff?
The company reported three deaths in the trial, though none were associated with its experimental drug gedatolisib.